High Specificity of Quantitative Excision Repair Cross-Complementing 1 Messenger RNA Expression for Prediction of Minor Histopathological Response to Neoadjuvant Radiochemotherapy in Esophageal Cancer
Open Access
- 1 June 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (11), 3794-3799
- https://doi.org/10.1158/1078-0432.ccr-03-0079
Abstract
Purpose: The excision repair cross-complementing 1 (ERCC1) gene is coding for a nucleotide excision repair protein involved in the repair of radiation- and chemotherapy-induced DNA damage. We examined the potential of quantitative ERCC1 mRNA expression to predict minor or major histopathological response to neoadjuvant radiochemotherapy (cisplatin, 5-fluorouracil, and 36 Gy of radiation) followed by transthoracic en bloc esophagectomy in patients with locally advanced esophageal cancer (cT2–4, Nx, M0). Experimental Design: Tissue samples were collected by endoscopic biopsy before treatment. RNA was isolated from biopsies, and quantitative real-time reverse transcriptase PCR assays were performed to determine ERCC1 mRNA expression. Relative mRNA levels (tumor/normal ratios) were calculated as (ERCC1/β-actin in tumor)/(ERCC1/β-actin in paired normal tissue). ERCC1 expression levels were correlated with the objective histopathological response in resected specimens. Histomorphological regression was defined as major response when resected specimens contained 1.09 were not associated with a major histopathological response (sensitivity, 62.5%; specificity, 100%) and 15 of 24 patients with minor histopathological response to the delivered neoadjuvant radiochemotherapy could be unequivocally identified. This association of dichotomized relative ERCC1 mRNA expression and histopathological response was statistically significant (P < 0.001). Conclusions: Relative expression levels of ERCC1 mRNA determined by quantitative real-time reverse transcriptase-PCR appear highly specific to predict minor response to our neoadjuvant radiochemotherapy protocol in patients with locally advanced esophageal cancer and could be applied to prevent expensive, noneffective, and potentially harmful therapies in a substantial number (42%) of patients.Keywords
This publication has 25 references indexed in Scilit:
- Biochemical Analysis of the Damage Recognition Process in Nucleotide Excision RepairPublished by Elsevier BV ,2003
- Frequency of Nodal Metastases to the Upper Mediastinum in Barrett's CancerAnnals of Surgical Oncology, 2002
- Expression von Genen mit möglicher prognostischer Bedeutung für das Ansprechen auf Chemotherapie bei Patienten mit Osteosarkom - Gene mit möglicher prognostischer Bedeutung beim Osteosarkom -Klinische Padiatrie, 2002
- Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trialThe Lancet, 2002
- Human DNA Repair GenesScience, 2001
- ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cellsInternational Journal of Cancer, 2000
- Preoperative risk analysis in patients with adenocarcinoma or squamous cell carcinoma of the oesophagusBritish Journal of Surgery, 2000
- Action of DNA Repair Endonuclease ERCC1/XPF in Living CellsScience, 1999
- Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessmentZeitschrift für Krebsforschung und Klinische Onkologie, 1997
- The importance of the ERCC1ERCC4[XPF] complex for hypoxic-cell radioresistance does not appear to derive from its participation in the nucleotide excision repair pathwayMutation Research/DNA Repair, 1996